

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA **复星医药**

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

VOLUNTARY ANNOUNCEMENT IN RELATION TO THE REPURCHASE OF H SHARES

This announcement is made on a voluntary basis by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”).

In order to preserve the value of the Company, pursuant to the general mandate (the “**H Share Repurchase Mandate**”) to repurchase H shares of the Company (the “**H Shares**”) granted to the board of directors of the Company (the “**Board**”) by the shareholders of the Company at the annual general meeting, the class meeting of H shareholders, and the class meeting of A shareholders of the Company held on 16 June 2026 and the relevant authorization granted by the Board, on 27 August 2026, the Company repurchased H Shares. A total of 217,000 H Shares were repurchased on the open market on the same day at an average price of HKD16.53 per share, for an aggregate repurchase amount of approximately HKD3.5870 million, with the highest price being HKD16.59 per share and the lowest price being HKD16.45 per share.

The Company will hold the repurchased H Shares as treasury shares, the use of which will be determined by the Company in accordance with the H Share Repurchase Mandate and factors such as market conditions, including but not limited to cancellation.

By Order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
27 August 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* For identification purposes only